Ryvu Therapeutics SA
WSE:RVU
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.72
34.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| PL |
R
|
Ryvu Therapeutics SA
WSE:RVU
|
621.9m PLN |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
238.1B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
167.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
83T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.9B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.5B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
277.7B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
29.1B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
20.3B EUR |
Loading...
|
Market Distribution
| Min | -10 083 900% |
| 30th Percentile | -1.5% |
| Median | 5.4% |
| 70th Percentile | 11.7% |
| Max | 195 905.3% |
Other Profitability Ratios
Ryvu Therapeutics SA
Glance View
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Ryvu Therapeutics SA is -174.5%, which is below its 3-year median of -164.7%.
Over the last 3 years, Ryvu Therapeutics SA’s Operating Margin has increased from -450.1% to -174.5%. During this period, it reached a low of -450.1% on Sep 30, 2022 and a high of -96% on Jun 30, 2023.